Tilray Brands, Inc.
TLRYTilray Brands, Inc. is an American pharmaceutical, cannabis-lifestyle and consumer packaged goods company, incorporated in the United States, headquartered in New York City. Tilray also has operations in Canada, Australia, New Zealand,Latin America, with growing facilities in Germany, Portugal and the United Kingdom.
Drugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How TLRY's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
High THC/Low CBD Cannabis | Phase 2 | Posttraumatic Stress Disorder | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in Tilray Brands, Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Tilray Brands, Inc.'s (TLRY) pipeline across Phase 2. Its lead program is High THC/Low CBD Cannabis (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Tilray Brands, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Tilray Brands, Inc. (TLRY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track TLRY biotech catalysts?→
Add TLRY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Tilray Brands, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.